AstraZeneca PLC (AZN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2023)
AZN's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
AZN Revenue Analysis (2014–2025)
As of March 2, 2026, AstraZeneca PLC (AZN) generated trailing twelve-month (TTM) revenue of $58.74 billion, reflecting modest growth of +4.1% year-over-year. The most recent quarter (Q4 2025) recorded $15.50 billion in revenue, up 2.1% sequentially.
Looking at the longer-term picture, AZN's 5-year compound annual growth rate (CAGR) stands at +17.2%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $58.74 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows AZN's business is primarily driven by Total Oncology (21%), CVRM (13%), and Rare Disease (10%).
When compared to Healthcare sector peers including LLY (+45.4% YoY), JNJ (+3.7% YoY), and BMY (+1.3% YoY), AZN has underperformed the peer group in terms of revenue growth. Compare AZN vs LLY →
Peer Comparison
Compare AZN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AZNCurrent | $58.7B | +4.1% | +17.2% | 23.4% | |
| LLY | $45.0B | +45.4% | +15.1% | 38.9% | |
| JNJ | $88.8B | +3.7% | +1.6% | 24.9% | |
| BMY | $48.3B | +1.3% | +13.1% | 20.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $58.74B | +8.6% | $48.11B | 81.9% | $13.74B | 23.4% |
| 2024 | $54.07B | +18.0% | $43.87B | 81.1% | $10.00B | 18.5% |
| 2023 | $45.81B | +3.3% | $37.54B | 82.0% | $8.19B | 17.9% |
| 2022 | $44.35B | +18.5% | $31.96B | 72.1% | $3.76B | 8.5% |
| 2021 | $37.42B | +40.6% | $24.98B | 66.8% | $1.06B | 2.8% |
| 2020 | $26.62B | +9.2% | $21.32B | 80.1% | $5.16B | 19.4% |
| 2019 | $24.38B | +10.4% | $19.46B | 79.8% | $2.92B | 12.0% |
| 2018 | $22.09B | -1.7% | $17.15B | 77.7% | $3.39B | 15.3% |
| 2017 | $22.46B | -2.3% | $18.15B | 80.8% | $3.68B | 16.4% |
| 2016 | $23.00B | -6.9% | $18.88B | 82.1% | $4.90B | 21.3% |
See AZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AZN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare AZN vs AGIO
See how AZN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is AZN's revenue growth accelerating or slowing?
AZN revenue growth slowed to +4.1%, below the 5-year CAGR of +17.2%. TTM revenue is $58.7B. The deceleration marks a shift from historical growth rates.
What is AZN's long-term revenue growth rate?
AstraZeneca PLC's 5-year revenue CAGR of +17.2% reflects the variable expansion pattern. Current YoY growth of +4.1% is near this long-term average.
How is AZN's revenue distributed by segment?
AZN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.